ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: cardiovascular disease

As Population Ages, Rheumatologists Prepare to Treat Elderly Patients with More Comorbidities

  |  

Cardiovascular disease, diabetes are among the conditions that add another layer of complexity in treating older rheumatology patients

Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review Course

  |  

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.

Gout & Cardiometabolic Co-Morbidities

  |  

ACR Convergence 2025 experts explore gout’s deep ties to MetS, insulin resistance and cardiovascular mortality, weighing new data on colchicine, febuxostat and SGLT2 inhibitors.

Let’s Discuss: Insights from the ACR Convergence 2025 Review Course

  |  

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.

Study: Are TNF Inhibitors Safe for Patients with RA-ILD?

Bryn Nelson, PhD  |  

Despite anecdotal reports to the contrary, a large observational study concludes that TNF inhibitors, compared with non-TNF biological or targeted synthetic DMARDs, do not cause higher rates of death or respiratory hospitalization in patients with RA-ILD.

Complications: Renal Arteriosclerosis in Patients with Lupus Nephritis

  |  

Renal arteriosclerosis is common in patients with lupus nephritis and occurs two decades earlier than it does in people without the condition, say investigators in a study that examined the prevalence of renal arteriosclerosis in patients with lupus nephritis compared with healthy controls.1 The finding suggests that renal arteriosclerosis could be used as a biomarker…

Atherosclerosis in Patients with SLE & the Risk of Progression: A 10-Year View

  |  

Research from Papazoglou et al. highlights the substantial risk of atherosclerosis progression and incident cardiovascular events in patients with systemic lupus erythematosus, as well as the importance of prolonged remission and the sustained control of cardiovascular risk factors in mitigating these risks over time.